Stemming the Tide: Is Long-acting, IM Octreotide Injection Better than Standard of Care for Angiodysplasia-related GI Bleeding?
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Philip Okafor, MD, MPH discuss “Standard of care versus octreotide in angiodysplasia-related bleeding: a multicenter randomized control trial,” by Goltstein L, Grooteman KV, Bernts LH et al. Gastroenterology 2024; 155: 690-703):1649-1659.